<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253626</url>
  </required_header>
  <id_info>
    <org_study_id>54788</org_study_id>
    <nct_id>NCT04253626</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Ferrous Sulfate to Intravenous Ferric Carboxymaltose in Antepartum Iron Deficiency Anemia</brief_title>
  <official_title>Comparison of Oral Ferrous Sulfate to Intravenous Ferric Carboxymaltose in Antepartum Iron Deficiency Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the extent to which treatment of iron deficiency anemia beyond 28 weeks' gestation
      of pregnancy with intravenous iron increases hemoglobin compared to oral iron. The
      investigators will test the hypothesis that pregnant women who are anemic in the third
      trimester are more likely to significantly increase their hemoglobin with intravenous iron as
      opposed to the usual standard of care, oral iron.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Hemoglobin value before and after intervention</measure>
    <time_frame>From the date of randomization to four weeks after the intervention</time_frame>
    <description>Hemoglobin is measured as g/dL at enrollment and after the study intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Pregnancy Related</condition>
  <condition>Anemia, Iron Deficiency</condition>
  <arm_group>
    <arm_group_label>Intravenous iron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 750mg intravenous iron ferric carboxymaltose, with a maximum of 2 doses based on the baseline hemoglobin level. The ferric carboxymaltose is administered as an infusion for approximately 15 - 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral iron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery. For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin &lt; 9.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>750mg intravenous ferric carboxymaltose</description>
    <arm_group_label>Intravenous iron</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous Sulfate</intervention_name>
    <description>325mg oral ferrous sulfate</description>
    <arm_group_label>Oral iron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant patients 18 years old and above,

          2. Planning to deliver at Lucile Packard Children's Hospital at Stanford,

          3. With Hemoglobin &lt;10.5 g/dL and ferritin &lt;30µg/L in second trimester, OR Hemoglobin &lt;11
             g/dL and ferritin &lt;30µg/L by third trimester

          4. Hemodynamically stable

        Exclusion Criteria:

          1. Known/suspected hemoglobinopathy such as i. Sickle cell disease ii. Beta-thalassemia
             iii. Alpha thalassemia

          2. Vitamin B12 or Folate deficiency

          3. Previous allergic reaction to intravenous iron,

          4. Serum pre-treatment ferritin levels &gt;300 ng/mL,

          5. Hypophosphatemia (serum phosphorus levels &lt; 2)

          6. Chronic infectious disease (such as HIV, Hepatitis)

          7. Known malignancy

          8. Known chronic kidney disease/ ESRD

          9. Hemoglobin &lt; 7 g/dL
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre Lyell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Girsen</last_name>
    <phone>6504604902</phone>
    <email>agirsen@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imee Datoc</last_name>
    <phone>6507255720</phone>
    <email>idatoc@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University School of Medicine/Lucile Packard Childrens Hospital</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 31, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Deirdre Judith Lyell</investigator_full_name>
    <investigator_title>Professor, Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

